Clinical trialPhase 2Completed
Combination Chemotherapy, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer
A Phase II Study Of Neo-Adjuvant Chemotherapy And Radiation In Patients With Locally Advanced Pancreatic Cancer
- Outcome
- Results posted; single-arm, no comparison
- Phase
- Phase 2
- Status
- Completed
- Study type
- Interventional
- Start
- 25 February 2004
- Ended
- 1 December 2014
- Enrollment
- 29 participants
- Sites
- 1
- Primary outcomes
- Surgical Exploration; Number of Participants Experiencing Grade 3-4 Toxicity While Receiving the Study Treatment
- Sponsor type
- Academic / other
- Results posted
- 21 October 2019
- Last update
- 29 September 2023
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Results
- Primary endpoint
- Results posted; single-arm, no comparisonAs posted on ClinicalTrials.gov ↗, registry record of 29 September 2023
- Primary outcome
- Surgical Explorationunresectable disease: Treatment: 4 of 19intra-abdominal metastasis: Treatment: 6 of 19resection of the primary tumor: Treatment: 9 of 19Values: ParticipantsTime frame: After 6 weeks of chemotherapy and then after 4 weeks of chemo-radiation.No analysis posted for this outcome (outcome 1)
- Primary outcome
- Number of Participants Experiencing Grade 3-4 Toxicity While Receiving the Study TreatmentInduction CT, grade 3: Treatment: 4 of 29Induction CT, grade 4: Treatment: 5 of 29CRT, grade 3: Treatment: 11 of 27CRT, grade 4: Treatment: 0 of 27Within 1 mo. post CRT, grade 3: Treatment: 12 of 27Within 1 mo. post CRT, grade 4: Treatment: 1 of 27Values: ParticipantsTime frame: From time of first dose until 30 days following final treatment, approximately 24 weeks6 of 8 rows shownNo analysis posted for this outcome (outcome 2)
- Participants
- Treatment: 29 started, 24 completed
- Serious adverse events
- Treatment: 25 of 29Participants with at least one serious adverse event, of those at risk, as posted
Every value is copied from the trial’s results record at ClinicalTrials.gov. “Statistically significant” describes the posted test only: it does not say which group did better, and nothing here is read from a paper.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Giving combination chemotherapy with radiation therapy before surgery may shrink the tumor so that it can be removed. PURPOSE: This phase II trial is studying how well giving combination chemotherapy together with radiation therapy works in treating patients who may undergo surgery for locally advanced pancreatic cancer.
Detailed description public domain (ClinicalTrials.gov)
OBJECTIVES: * Determine the antitumor and clinical benefit response to neoadjuvant chemoradiotherapy comprising gemcitabine, fluorouracil, leucovorin calcium, and oxaliplatin in patients with potentially resectable locally advanced adenocarcinoma of the pancreas. * Determine the toxic effects of this regimen in these patients. * Determine the achieved steady-state plasma levels of gemcitabine and fluorouracil in these patients and correlate these plasma levels with clinical toxicity associated with this regimen. * Determine the potential importance of polymorphic variations in genomic DNA of pertinent genes (whose protein products are targets of the antineoplastic drugs used in this study) on response to and toxicity of this regimen in these patients. * Determine the gene expression profiles of primary and metastatic pancreatic tumors before and after treatment with this regimen. OUTLINE: * Neoadjuvant chemotherapy: Patients receive gemcitabine IV over 30 minutes and fluorouracil IV continuously over 24 hours on days 2 and 9, and leucovorin calcium orally on days 1 and 8 and IV on days 2 and 9. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. * Neoadjuvant chemoradiotherapy: Beginning on day 42, patients undergo chemoradiotherapy comprising oxaliplatin IV over 2 hours on days 42, 49, 56, 63, 70, and 77 and fluorouracil IV continuously on days 42-78 with external beam radiotherapy. * Surgery: Patients undergo surgical resection 42-56 days after completion of chemoradiotherapy. * Adjuvant chemotherapy: After post-operative recovery, patients receive 2 additional courses of gemcitabine, fluorouracil, and leucovorin calcium. If surgical resection is not possible, patients with stable or responsive disease resume gemcitabine, fluorouracil, and leucovorin calcium indefinitely in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months. PROJECTED ACCRUAL: A total of 50 patients will be accrued for this study.
Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)
Surgical Exploration [After 6 weeks of chemotherapy and then after 4 weeks of chemo-radiation.]. Count Of Participants, Participants. unresectable disease: Treatment (n=19): 4. intra-abdominal metastasis: Treatment (n=19): 6. resection of the primary tumor: Treatment (n=19): 9.
Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)
Number of Participants Experiencing Grade 3-4 Toxicity While Receiving the Study Treatment [From time of first dose until 30 days following final treatment, approximately 24 weeks]. Count Of Participants, Participants. Induction CT, grade 3: Treatment (n=29): 4. Induction CT, grade 4: Treatment (n=29): 5. CRT, grade 3: Treatment (n=29): 11. CRT, grade 4: Treatment (n=29): 0. Within 1 mo. post CRT, grade 3: Treatment (n=29): 12. Within 1 mo. post CRT, grade 4: Treatment (n=29): 1. 2-3 mos. post CRT, grade 3: Treatment (n=29): 9. 2-3 mos. post CRT, grade 4: Treatment (n=29): 0.